ClinicalTrials.gg
CompletedNCT02220712Updated Jan 25, 2021Results posted

A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia

A Phase 1 interventional study of OPC-14597 IMD in Schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 5 sites in Japan. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
115th of 125
17 · median 130
Started
2014
with 5 others
Phase 1
13 of 126
none open now
Registered
87th of 126
by date
Lead sponsor
4 of 126
Otsuka Pharmaceutical Co., Ltd.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 115th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2014, is one of 13 in phase 1, and was the 87th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To assess the pharmacokinetics and safety of aripiprazole intra-muscular (IM) depot formulation in patients with schizophrenia after repeated administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Aripiprazole
  • Deltoid
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual (DSM)-IV-Text Revision (TR) (295.30, 295.10, 295.20, 295.90, 295.60)
  • Patients who have provided written by themselves (If the patient is a minor, written consent from a legal representative must be obtained in addition to the patient's own written informed consent.)
  • Patients, both male and female, aged 18 years or older, but younger than 65 years, at the time of obtaining informed consent
  • Patients with a of 18.5 or higher and lower than 35.0
  • Patients whose mental condition is stable or well maintained for 2 weeks or more without any change to dosage regimen for their non-aripiprazole oral atypical antipsychotic monotherapy prior to obtaining informed consent
  • Patients who have received aripiprazole in the past

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed as having a mental disorder other than schizophrenia, as defined by criteria.
  • Patients with a history or complication of diabetes.
  • Patients with hepatic, renal, cardiac, or hematopoietic disorders.
  • Female patients who are pregnant or lactating, who may possibly be pregnant, who wish to become pregnant, or male patients whose partner wishes to become pregnant.
  • Patients who have a drug allergy or drug
  • Patients for whom clozapine has been ineffective, patients who have responded only to clozapine, or patients who are currently being treated with clozapine.
  • Patients with a complication of Parkinson's Disease (excluding drug-induced Parkinsonism).
  • Patients with a history or a complication of neuroleptic malignant syndrome, rhabdomyolysis, tardive dyskinesia, paralytic ileus or water intoxication.
  • Patients with a history or a complication of psychological or behavioral abnormalities associated with use of psychoactive substances (abuse of alcohol, narcotics, or organic solvent, etc).
  • Patients with a history or a complication of suicide attempt or self-injury within 52 weeks prior to obtaining .
  • Patients with a history of or a complication of convulsive disorder such as epilepsy.
  • Patients with a history of or a complication of organic brain disorder including cerebrovascular disease.
  • Patients with a history or a complication of granulocytopenia or agranulocytosis.
  • Patients who have received electro-convulsive therapy (ECT) within 12 weeks prior to obtaining informed consent.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Drug: OPC-14597 IMD

    Drug: OPC-14597 IMD

Interventions

  • Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals

06

What researchers measure

Primary outcomes

  1. OPC-14597 Plasma Concentration 672 Hours Postdose Following Multiple Administration of OPC-14597 IMD Injections

    Time frame: 672 hours postdose of the first, second, third, fourth, and fifth IMD injections

07

Results

Posted Jan 25, 2021

Participant flow

Participant flow — Overall Study
MilestoneOPC-14597 IMD
Started17
Completed13
Not completed4
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2
Withdrew: Exacerbation of symptoms of an underlying disease1

Outcome measures

PrimaryOPC-14597 Plasma Concentration 672 Hours Postdose Following Multiple Administration of OPC-14597 IMD Injections
Time frame:
672 hours postdose of the first, second, third, fourth, and fifth IMD injections
Reported as:
Mean · ng/mL
OPC-14597 Plasma Concentration 672 Hours Postdose Following Multiple Administration of OPC-14597 IMD Injections
ng/mLOPC-14597 IMD (First Dose)OPC-14597 IMD (Second Dose)OPC-14597 IMD (Third Dose)OPC-14597 IMD (Fourth Dose)OPC-14597 IMD (Fifth
OPC-14597 Plasma Concentration 672 Hours Postdose Following Multiple Administration of OPC-14597 IMD Injections91.9 ± 29.4141 ± 54.0171 ± 76.1198 ± 102201 ± 88.9

Adverse events

Collected over 20 weeks of treatment period + posttreatment observation period (57 days after administration of the fifth IMD). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-14597 IMD0/17 (0%)2/17 (11.8%)15/17 (88.2%)
Most frequent serious events
Most frequent serious events
EventOPC-14597 IMD
SchizophreniaPsychiatric disorders1/17
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/17
Most frequent other events
Showing 10 of 26
Most frequent other events
EventOPC-14597 IMD
Injection site painGeneral disorders6/17
NasopharyngitisInfections and infestations5/17
Weight increasedInvestigations3/17
SchizophreniaPsychiatric disorders2/17
InsomniaPsychiatric disorders2/17
HeadacheNervous system disorders2/17
Hepatic function abnormalHepatobiliary disorders2/17
Injection site indurationGastrointestinal disorders2/17
Injection site swellingGeneral disorders2/17
PharyngitisInfections and infestations1/17

Baseline characteristics

Safety analysis set included subjects who received aripiprazole IMD at least once and who had safety data after aripiprazole IMD administrationn.

Age, Categorical
Age, Categorical(Participants)OPC-14597 IMD
<=18 years0
Between 18 and 65 years17
>=65 years0
Age, Continuous
Age, Continuous(years)OPC-14597 IMD
Mean39.2 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)OPC-14597 IMD
Female5
Male12
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OPC-14597 IMD
Japanese17
Region of Enrollment
Region of Enrollment(participants)OPC-14597 IMD
Japan17
08

Study locations

5 sites
  • Chugoku Region, Japan
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2021, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2014
First posted
Aug 20, 2014
Start
Jul 2014
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Jan 25, 2021
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02220712
Responsible party
Sponsor
First posted
Aug 20, 2014
Start date
Jul 2014
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Jan 25, 2021
Last update
Jan 25, 2021

Study contacts

Jun-ichi Hashimoto, PhD
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion